Urisu A, Iimi K, Kondo Y, Horiba F, Masuda S, Tsuruta M, Yazaki T, Torii S
Department of Pediatrics, Fujita Health University School of Medicine.
Arerugi. 1990 Oct;39(10):1448-54.
Amlexanox, an anti-allergic drug, showed a concentration-dependent inhibition against hrIL-3-induced enhancement of in vitro histamine release from human leukocytes by anti-IgE. The significant inhibitory action of amlexanox was observed in one out of nine and six out of nine allergic subjects at concentrations of 10(-5) M and 10(-4) M, respectively. This means that the inhibitory effect of amlexanox varied from patient to patient. Post-treatment as well as simultaneous treatment with amlexanox produced an inhibitory action on the enhancing effect of hrIL-3, suggesting that hrIL-3-induced enhancement of releasability is a reversible reaction. AA-861, OKY-046, superoxide dismutase and prostaglandin E2 showed no effects on the hrIL-3-induced enhancement of histamine releasability. The inhibitory action of amlexamox to the hrIL-3-induced enhancement of histamine releasability may be a new anti-allergic mechanism, details of which remains unclear.
抗组胺药氨来呫诺对人白细胞在抗IgE作用下hrIL-3诱导的体外组胺释放增强具有浓度依赖性抑制作用。在9名过敏受试者中，分别有1名和6名在10(-5)M和10(-4)M浓度下观察到氨来呫诺有显著抑制作用。这意味着氨来呫诺的抑制作用因患者而异。氨来呫诺治疗后以及同时治疗对hrIL-3的增强作用均产生抑制作用，提示hrIL-3诱导的释放能力增强是可逆反应。AA-861、OKY-046、超氧化物歧化酶和前列腺素E2对hrIL-3诱导的组胺释放增强无作用。氨来呫诺对hrIL-3诱导的组胺释放增强的抑制作用可能是一种新的抗过敏机制，其具体细节尚不清楚。
